SEC Filing Summary: Sunshine Heart, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sunshine Heart, Inc. on February 2, 2017. The filing reports corporate governance changes effective as of the filing date, specifically the appointment of two new members to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The Board of Directors increased the size of the Board to six members and appointed two new directors to fill vacancies:
- Steve Brandt: Appointed as a Class I director. He brings over 35 years of healthcare industry experience, including roles as Vice President of Global Sales and Marketing at Thoratec Corporation and previous leadership positions at CHF Solutions and St. Jude Medical.
- Matthew E. Likens: Appointed as a Class II director. He is a principal at Likens Healthcare and Management Consulting, LLC, and formerly served as President and CEO of Ulthera, Inc. and President of Baxter's Renal U.S. business.
Compensation and Governance Details
Both appointees are non-employee directors and will participate in the standard compensation program:
- Base Retainer: $55,000 annually.
- Equity Award: An annual award with an aggregate value of $35,000 on the grant date. For these appointments, the award is pro-rated based on the time elapsed since the preceding annual meeting.
- Equity Structure: One-third of the equity award is issued as options, and two-thirds as restricted stock units (RSUs).
- Indemnity: The Company entered into standard Indemnity Agreements with both directors on February 2, 2017.
Investor Verification Checklist
- Verify the biographical details and potential conflicts of interest for Steve Brandt and Matthew E. Likens via the definitive proxy statement (Schedule 14A) filed on May 26, 2016.
- Confirm the pro-rata calculation of the initial equity grants for the new directors.
- Review the press release dated February 3, 2017 (Exhibit 99.1) for additional context on the appointments.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial performance metrics.